PLANNING INTERDISCIPLINARY STUDIES OF DIABETIC HEART: TECNOLOGY PLATFORM DVMT

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定为研究者机构。技术平台开发：我们将参与建立一个技术平台的计划，以实现基本发现途径的活动。这些技术还将为面向患者的研究人员提供必要的复杂资源，以将发现转化为开发新的患者护理工具。该平台将在华盛顿大学的BioMed 21背景下开发。该平台将由技术中心的核心组成，这些技术中心配备有为基础和临床研究人员提供高通量检测技术、高度注释的患者标本和生物学工具包集合的能力。这些资源将加速开发经过充分验证的生物标志物，并促进开发新疗法所需的机制发现。技术平台中心将在理事会的监督下，由探索计划小组的专家成员开发和管理。一些相关的中心是：高通量细胞筛选，转化病理学，应用基因组学，代谢组学，纳米技术和蛋白质组学

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Technology Platform Development: We will engage in plan to establish a Technology platform to enable the activities of the Fundamental Discovery Pathways. The technologies will also provide the sophisticated resources necessary for the patient-oriented researchers to translate discovery to develop new tools for patient care. This platform will be developed within the context of BioMed 21 at Washington University. The Platform will be composed of cores of Technological Centers equipped to provide both basic and clinical investigators access to high-throughput assay technologies, highly annotated patient specimens, and collections of biological toolkits. These resources will expedite the development of well-validated biomarkers and facilitate the mechanistic discoveries necessary for development of novel therapeutics. The Technology Platform Centers will be developed and managed by expert members of the Discovery planning groups with oversight by the Council. Some relevant Centers are: High-Throughput Cell Screening, Translational Pathology, Applied Genomics, Metabolomics, Nanotechnology, and Proteomi